NDAORALSUSPENSIONPriority Review
Approved
May 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
3/8 — Basic
Priority Review
VIOXX (rofecoxib) by Merck & Co.. Approved for postoperative pain, osteoarthritis, rheumatoid arthritis and 1 more indications. First approved in 1999.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIOXX (rofecoxib) is a selective COX-2 inhibitor oral suspension developed by Merck & Co. for the treatment of osteoarthritis, rheumatoid arthritis, acute pain, and postoperative pain. The drug was approved in May 1999 and represents a small-molecule NSAID designed to reduce gastrointestinal side effects compared to non-selective NSAIDs.
LOE Approaching
Product is in late-stage lifecycle with declining market exclusivity; commercial teams are likely focused on defending market share against newer biologics and managing transition strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (4)
Worked on VIOXX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.